@article {Shekhar2020.05.08.20096040, author = {Rahul Shekhar and Shubhra Upadhyay and Silvi Shah and Devika Kapuria}, title = {COVID-19 and Acute Kidney Injury Requiring Kidney Replacement Therapy: A Bad Prognostic Sign}, elocation-id = {2020.05.08.20096040}, year = {2020}, doi = {10.1101/2020.05.08.20096040}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The development of acute kidney injury in patients with COVID-19 is estimated to about 0.5\% from earlier studies from China. The incidence of AKI in patients with COIVID-19 in the largest inpatient series in the United States is 22.2\%3. Development of AKI requiring kidney replacement therapy in hospitalized patients is a bad prognostic sign. Out of Fifty patients admitted to our hospital with COVID-19 13/50(26\%) developed AKI. All patients required hospitalization in intensive care unit care and 12/13 required initiation of kidney replacement therapy. The median age was 41 years (31-85 years) and 50\% were men. Common comorbidities were obesity (83\%), diabetes (42\%), and hypertension (25\%). 10/12 (83\%) patients were hypoxemic and required oxygen therapy. 11/12 (92\%) patients required invasive ventilation. Majority of patients had elevated neutrophils counts (81.8\%) and low lymphocyte counts (81.8\%). All patients had chest x-ray findings suggestive of pneumonia. 11/12(91.6\%) developed septic shock requiring vasopressors. Review of UA showed all patient (9/9) had active urine sediments with blood but 7/9 of them have sterile pyuria. At the end of study period, 1 patient remained hospitalized. 10/11(90\%) patients died and one patient was discharged home with resolution of AKI. Median length of stay was 13 days. The exact mechanism of AKI is not well understood in COVID-19 but can be due to acute tubular necrosis due to septic shock because of cytokine storm in severe COVID-19 or direct invasion by SARS-CoV-2 on podocytes and proximal renal tubular cells. Our findings suggest poor prognosis despite continuous kidney replacement therapies in patients who develop AKI with COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNon Funded studyAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is collect by two independent MD RS, SU and stored in redcap in deidentified formatWHOWorld Health OrganizationUSUnited StatesAKIAcute Kidney InjuryCtComputed tomographyICUIntensive care unitARDSAcute respiratory distress syndromeCRRTContinuous renal replacement therapyHDHemodialysis}, URL = {https://www.medrxiv.org/content/early/2020/05/14/2020.05.08.20096040}, eprint = {https://www.medrxiv.org/content/early/2020/05/14/2020.05.08.20096040.full.pdf}, journal = {medRxiv} }